适应症
试验速览
- 阶段
- 3 期
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
入选标准
- •-Patient, age 20 years or older
- •-Patients with urinary frequency and urge urinary incontinence
- •Exclusion criteria:
- •-Patients who have diseases such as dysuria or urinary retention
- •-Patients who have difficulty to void for myself
- •-Patients with other diseases which may have been related to the state of urination. (ex urinary tract infection)
- •-Patients with polyuria
- •-Patients with diseases for which treatment with anticholinergic agents is contraindicated
- •-Patients in whom precautions are required for the use of anticholinergic agents
- •-Patients who have difficulty to use transdermal medications
排除标准
- 未提供
研究者
相似试验
未知
3 期
CS-801 phase 3 comparative studyOveractive bladderJPRN-jRCT2080220025Sankyo Co.,Ltd.
进行中（未招募）
不适用
A phase III long-term follow-up study to assess the immune responses following vaccination at 36-46 months of age with a booster dose of GSK Biologicals’ 10-valent pneumococcal conjugate vaccine (10Pn-PD-DiT) and to evaluate the immunogenicity and safety of a 2-dose catch-up immunization course with the 10Pn-PD-DiT vaccine in the fourth year of life. - 10PN-PD-DIT-046 EXT:002 Y2A booster vaccination study against Streptococcus pneumoniae in subjects aged 36-46 months and a two-dose vaccination against Streptococcus pneumoniae of age-matched unprimed children.EUCTR2008-003950-14-SEGlaxoSmithKline Biologicals210
进行中（未招募）
1 期
A phase III long-term follow-up study to assess the immune responses following vaccination at 36-46 months of age with a booster dose of GSK Biologicals’ 10-valent pneumococcal conjugate vaccine (10Pn-PD-DiT) and to evaluate the immunogenicity and safety of a 2-dose catch-up immunization course with the 10Pn-PD-DiT vaccine in the fourth year of life. - 10PN-PD-DIT-046 EXT:002 Y2A booster vaccination study against Streptococcus pneumoniae in subjects aged 36-46 months and a two-dose vaccination against Streptococcus pneumoniae of age-matched unprimed children.EUCTR2008-003950-14-SKGlaxoSmithKline Biologicals210
已完成
3 期
K-924-03HypercholesterolemiaJPRN-jRCT2080225088Kowa Company, Ltd.110
进行中（未招募）
1 期
A Phase 3, Long-Term Extension Study to Evaluate the Safety and Efficacy of Imsidolimab (ANB019) in the Treatment of Adult Subjects with Generalized Pustular PsoriasisSubjects with generalized pustular psoriasisMedDRA version: 20.0Level: PTClassification code 10037575Term: Pustular psoriasisSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersEUCTR2021-001448-90-FRAnaptysBio Inc.45